scholarly journals Pharmacology of Meloxicam, A New Non-Steroidal Anti-Inflammatory Drug with an Improved Safety Profile Through Preferential Inhibition of COX-2

Rheumatology ◽  
1996 ◽  
Vol 35 (suppl 1) ◽  
pp. 4-12 ◽  
Author(s):  
G. Engelhardt
2018 ◽  
Vol 77 ◽  
pp. 568-578 ◽  
Author(s):  
Khaled R.A. Abdellatif ◽  
Wael A.A. Fadaly ◽  
Yaseen A.M.M. Elshaier ◽  
Waleed A.M. Ali ◽  
Gehan M. Kamel

Synlett ◽  
2017 ◽  
Vol 29 (01) ◽  
pp. 121-125 ◽  
Author(s):  
Andreas Kirschning ◽  
Heiko Sommer ◽  
Max Braun ◽  
Benjamin Schröder

4-Ethoxy-1,1,1-trifluoro-3-buten-2-one (ETFBO) serves as a trifluoromethyl-containing building block for the preparation of trifluoromethyl-substituted thiophenes, furans, pyrrols, and piperazines. Key steps are an addition–elimination reaction to ETFBO followed by the thiazolium-catalyzed Stetter reaction. The scope of this chemistry was demonstrated in a new synthetic approach towards the COX-2 selective, nonsteroidal anti-inflammatory drug Celebrex® (celecoxib).


MedChemComm ◽  
2019 ◽  
Vol 10 (10) ◽  
pp. 1775-1788 ◽  
Author(s):  
Marwa F. Harras ◽  
Rehab Sabour ◽  
Omkulthom Mohamed Alkamali

Novel non-acidic lonazolac analogues with high COX-2 selectivity and good safety profile, having potential anti-inflammatory activity.


2002 ◽  
Vol 22 (12) ◽  
pp. 799-818 ◽  
Author(s):  
M. Del Tacca ◽  
R. Colucci ◽  
M. Fornai ◽  
C. Blandizzi

2010 ◽  
Vol 45 (7-8) ◽  
pp. 822-827 ◽  
Author(s):  
Christoph Hotz-Behofsits ◽  
Robert J Simpson ◽  
Matthew Walley ◽  
Ingvar T. Bjarnason

2004 ◽  
Vol 41 (1) ◽  
pp. 67-75 ◽  
Author(s):  
Sevim Bavbek ◽  
Gülfem Çelik ◽  
Faruk Özer ◽  
Dilşad Mungan ◽  
Zeynep Mısırlıgil

Sign in / Sign up

Export Citation Format

Share Document